Literature DB >> 2502410

Current concepts in cryptococcosis.

T F Patterson1, V T Andriole.   

Abstract

Cryptococcus neoformans has become an increasingly important pathogen. Cryptococcosis is an important cause of morbidity and mortality in immunocompromised hosts and is the second most common fungal infection complicating AIDS. In recent years, research has focused on the host defenses against Cryptococcus and has led to an improved understanding of the capsular virulence of the organism, the mechanisms of T-cell defenses, and the role of phagocytic cells in the fungistasis and killing of cryptocci. Amphotericin B with or without flucytosine has clearly improved treatment of cryptococcosis, but therapy is associated with significant toxicity. Current investigation is focused on the triazoles, which may offer improved therapy for cryptococcosis. In this report, we review recent developments in the understanding of the host defenses against Cryptococcocus and discuss current recommendations for the management of cryptococcosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502410     DOI: 10.1007/bf01964060

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  107 in total

1.  Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.

Authors:  R A Fromtling; G K Abruzzo; G S Bulmer
Journal:  Mycopathologia       Date:  1986-04       Impact factor: 2.574

2.  Rapid selective urease test for presumptive identification of Cryptococcus neoformans.

Authors:  B L Zimmer; G D Roberts
Journal:  J Clin Microbiol       Date:  1979-09       Impact factor: 5.948

3.  Amphotericin B in cryptococcal meningitis. Long-term results of treatment.

Authors:  G A Sarosi; J D Parker; I L Doto; F E Tosh
Journal:  Ann Intern Med       Date:  1969-12       Impact factor: 25.391

4.  Immunization and complement interaction in host defense against murine Cryptococcosis.

Authors:  J R Graybill; J Ahrens
Journal:  J Reticuloendothel Soc       Date:  1981-11

5.  Diagnosis of cryptococcal meningitis.

Authors:  M P Berger; J Paz
Journal:  JAMA       Date:  1976-11-29       Impact factor: 56.272

6.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.

Authors:  A M Stamm; R B Diasio; W E Dismukes; S Shadomy; G A Cloud; C A Bowles; G H Karam; A Espinel-Ingroff
Journal:  Am J Med       Date:  1987-08       Impact factor: 4.965

7.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

8.  Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

9.  Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection.

Authors:  E J McManus; J M Jones
Journal:  J Clin Microbiol       Date:  1985-05       Impact factor: 5.948

10.  Cryptococcal meningitis. A review of 32 years experience.

Authors:  C N De Wytt; P L Dickson; G W Holt
Journal:  J Neurol Sci       Date:  1982-02       Impact factor: 3.181

View more
  15 in total

1.  New enzyme immunoassay for detecting cryptococcal antigen.

Authors:  F R Knight
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

2.  Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens.

Authors:  W Gade; S W Hinnefeld; L S Babcock; P Gilligan; W Kelly; K Wait; D Greer; M Pinilla; R L Kaplan
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

3.  Genetic relatedness and diversity of Cryptococcus neoformans strains in the Maltese Islands.

Authors:  C Lo Passo; I Pernice; M Gallo; C Barbara; F T Luck; G Criseo; A Pernice
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

Review 4.  Diagnosis of invasive mycoses in severely immunosuppressed patients.

Authors:  R Rüchel
Journal:  Ann Hematol       Date:  1993-07       Impact factor: 3.673

5.  Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies.

Authors:  M Lozano-Chiu; V L Paetznick; M A Ghannoum; J H Rex
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  A rare case of Cryptococcus luteolus-related tenosynovitis.

Authors:  L Hunter-Ellul; E D Schepp; A Lea; M G Wilkerson
Journal:  Infection       Date:  2014-01-31       Impact factor: 3.553

Review 7.  An update on Cryptococcus among HIV-infected patients.

Authors:  T Warkentien; N F Crum-Cianflone
Journal:  Int J STD AIDS       Date:  2010-10       Impact factor: 1.359

8.  Interference by hydroxyethyl starch used for vascular filling in latex agglutination test for cryptococcal antigen.

Authors:  L Millon; T Barale; M C Julliot; J Martinez; G Mantion
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948

9.  Disseminated intravascular coagulation associated with disseminated cryptococcosis in a patient with acquired immunodeficiency syndrome.

Authors:  G Fera; N Semeraro; V De Mitrio; O Schiraldi
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

10.  L3T4(CD4)-, Lyt-2(CD8)- and Mac-1(CD11b)-phenotypic leukocytes in murine cryptococcal meningoencephalitis.

Authors:  P Dobrick; K Miksits; H Hahn
Journal:  Mycopathologia       Date:  1995-09       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.